Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Cariou

Showing results (131-140 of 311) with videos related to

Pageof 32
Sort By:
Atherosclerosis|January 27, 2015
PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertensionJean-Mathieu Berger, Nathalie Vaillant, Cédric Le May, et al.
Medecine Sciences : M/S|October 14, 2021
[Hepatic organoids: What are the challenges?]Eléanor Luce, Antonietta Messina, Amandine Caillaud, et al.
Biochemical and Biophysical Research Communications|November 3, 2009
PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretionCédric Langhi, Cédric Le May, Valéry Gmyr, et al.
Diabetes Care|May 30, 2013
Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjectsBertrand Cariou, Rémy Hanf, Stéphanie Lambert-Porcheron, et al.
Diabetologia|June 8, 2015
The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasisAmélie Bonnefond, Loïc Yengo, Cédric Le May, et al.
Diabetes, Obesity & Metabolism|January 20, 2026
Methylglyoxal-glycated apolipoproteins A-I and A-II are associated with new-onset diabetes in individuals with prediabetesChloé Chevalier, Arsênio Rodrigues Oliveira, Matthieu Wargny, et al.
Atherosclerosis|May 14, 2025
Minigene splicing reporter assay: a high-stake tool for genetic diagnosis in familial hypobetalipoproteinemiaZoé Henry, Alexandre Janin, Séverine Nony, et al.
Vascular Diseases (Paris, France)|August 4, 2025
Analysis of differences in treating peripheral arterial disease in men and womenPauline Duprez-Larnier, Olivier Espitia, Jérôme Connault, et al.
Diabetes, Obesity & Metabolism|May 3, 2024
Empagliflozin mitigates metabolic dysfunction-associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetesSarra Smati, Thibaud Sotin, Perrine Deniel, et al.
Cardiovascular Diabetology|June 8, 2017
The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetesTrevor J Orchard, Bertrand Cariou, Margery A Connelly, et al.
Pageof 32

Showing results (131-140 of 311) with videos related to

Sort By:
Pageof 32
Atherosclerosis|January 27, 2015
PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertensionJean-Mathieu Berger, Nathalie Vaillant, Cédric Le May, et al.
Medecine Sciences : M/S|October 14, 2021
[Hepatic organoids: What are the challenges?]Eléanor Luce, Antonietta Messina, Amandine Caillaud, et al.
Biochemical and Biophysical Research Communications|November 3, 2009
PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretionCédric Langhi, Cédric Le May, Valéry Gmyr, et al.
Diabetes Care|May 30, 2013
Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjectsBertrand Cariou, Rémy Hanf, Stéphanie Lambert-Porcheron, et al.
Diabetologia|June 8, 2015
The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasisAmélie Bonnefond, Loïc Yengo, Cédric Le May, et al.
Diabetes, Obesity & Metabolism|January 20, 2026
Methylglyoxal-glycated apolipoproteins A-I and A-II are associated with new-onset diabetes in individuals with prediabetesChloé Chevalier, Arsênio Rodrigues Oliveira, Matthieu Wargny, et al.
Atherosclerosis|May 14, 2025
Minigene splicing reporter assay: a high-stake tool for genetic diagnosis in familial hypobetalipoproteinemiaZoé Henry, Alexandre Janin, Séverine Nony, et al.
Vascular Diseases (Paris, France)|August 4, 2025
Analysis of differences in treating peripheral arterial disease in men and womenPauline Duprez-Larnier, Olivier Espitia, Jérôme Connault, et al.
Diabetes, Obesity & Metabolism|May 3, 2024
Empagliflozin mitigates metabolic dysfunction-associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetesSarra Smati, Thibaud Sotin, Perrine Deniel, et al.
Cardiovascular Diabetology|June 8, 2017
The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetesTrevor J Orchard, Bertrand Cariou, Margery A Connelly, et al.
Pageof 32